Compare Canadian Natural Resources Ltd. (CNQ) vs Eli Lilly And Co (LLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Canadian Natural Resources Ltd. vs Eli Lilly And Co — how do they compare? Canadian Natural Resources Ltd. trades at $47.83 (market cap $98.11B), while Eli Lilly And Co trades at $1,221.34 (market cap $1.08T). The key difference: Eli Lilly And Co is far larger — about 11× Canadian Natural Resources Ltd.'s market cap, and Canadian Natural Resources Ltd. pays the higher dividend (3.73%). Which is the better fit depends on your goals.
| CNQ | LLY | |
|---|---|---|
Market Cap | $98.11B | $1.08T |
Sector | Energy | Health |
52-Week High | $50.55 | $1.24K |
52-Week Low | $29.31 | $639.43 |
Enterprise Value | $108.54B | $1.13T |
Dividend Yield | 3.73% | 0.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CNQ trades at $47.25, up 3.82% in 24 hours, with a bullish technical signal and strong earnings beats in recent quarters. The company reported Q2 2026 EPS of $1.53, exceeding expectations, and maintains robust profitability with a net income margin of 22.87%. Recent news highlights record production and a quarterly dividend of $0.63, reinforcing financial strength.
Outlook is positive due to low valuation multiples, consistent dividend payouts, and upward earnings revisions. Key risks include oil price volatility and rising debt levels. Analyst consensus is strongly bullish with 75% buy ratings, supporting potential upside if operational momentum continues.
Eli Lilly (LLY) trades at $1,231.58, up 3.87% in the past 24 hours, reflecting strong momentum near its 52-week high. The stock exhibits bullish technical signals with robust fundamentals, including 48% revenue growth in Q2 2026 and a net income margin of 33.53%. Recent news highlights legal actions against black-market drug sales and positive analyst sentiment following earnings beats.
Outlook remains positive with a consensus price target of $1,380, though high valuation ratios (P/E 40.79) and regulatory risks pose challenges. Earnings growth and pipeline advancements, like retatrutide, drive upside potential, but investors should monitor competitive pressures and execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Canadian Natural Resources Ltd.
Canadian Natural Resources is one of the largest oil and natural gas producers in western Canada, supplemented by operations in the North Sea and Offshore Africa. The company's portfolio includes light and medium oil, heavy oil, bitumen, synthetic oil, natural gas liquids, and natural gas. Production averaged 1.16 million barrels of oil equivalent per day in 2020, and the company estimates that it holds over 11.5 billion boe of proven and probable crude oil and natural gas reserves.
Read more on CNQ →About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →
